World

Loren Legarda Extends Medical Leave Until September 2

Senator Loren Legarda has officially extended her medical leave to September 2, as confirmed by Senate Secretary Renato Bantug.

25 August 2026Tagblick Newsdesk

AI-generatedWritten by an AI system, editorially responsible — how we work

Loren Legarda Extends Medical Leave Until September 2 — Photo: Pauline Balba · Wikimedia Commons · CC BY 2.0

Senator Loren Legarda has extended her medical leave to September 2, according to Senate Secretary Renato Bantug. This announcement was made on Monday, confirming her absence from the Senate plenary sessions and the impeachment trial of Vice President Sara Duterte.

Legarda's medical leave has been extended multiple times over the past month. Initially, she took leave from August 3 to 5, then extended it again from August 11 to 12, followed by another extension from August 17 to 19.

In the most recent notice, the extension covers the period from August 24 to September 2. During this time, her office communicated her absence to the Senate, signaling that she would not participate in ongoing legislative activities.

Archive photo: Loren Legarda Extends Medical Leave Until September 2 — Archive photoPhoto: paulinebalba · Flickr · BY

Bantug's confirmation noted that Legarda's leave affects both legislative sessions and the impeachment trial, highlighting the implications of her extended absence during a period of significant political activity.

According to the reports, this marks her fourth extension of medical leave, raising ongoing concerns regarding her health and ability to fulfill her duties as a senator.

This item was written by an AI system on the basis of the headlines and short teasers of the independently operating newsrooms named below. We disclose this under Art. 50(4), second subparagraph, of Regulation (EU) 2024/1689 (AI Act). Before publication we check origin and verifiability — anything that appears in only one place is not published — as well as language, substance and legally sensitive content. No separate substantive review of each individual item by a natural person takes place; we therefore do not rely on the exemption in Art. 50(4), second subparagraph, of the AI Act. Editorial responsibility for this publication rests with the person named in the imprint (§ 18 Abs. 2 MStV). Please report errors to [email protected] — we will correct or remove the item. Full reports are available from the sources listed.